GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (OTCPK:IPHYF) » Definitions » Accounts Payable

IPHYF (Innate Pharma) Accounts Payable : $16.76 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Accounts Payable?

Innate Pharma's Accounts Payable for the quarter that ended in Dec. 2024 was $16.76 Mil.

Innate Pharma's quarterly Accounts Payable increased from Dec. 2023 ($9.34 Mil) to Jun. 2024 ($9.42 Mil) and increased from Jun. 2024 ($9.42 Mil) to Dec. 2024 ($16.76 Mil).

Innate Pharma's annual Accounts Payable declined from Dec. 2022 ($14.47 Mil) to Dec. 2023 ($9.34 Mil) but then increased from Dec. 2023 ($9.34 Mil) to Dec. 2024 ($16.76 Mil).

Innate Pharma Accounts Payable Historical Data

The historical data trend for Innate Pharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Accounts Payable Chart

Innate Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.22 16.64 14.47 9.34 16.76

Innate Pharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.47 20.58 9.34 9.42 16.76

Innate Pharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Innate Pharma Accounts Payable Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (OTCPK:IPHYF) » Definitions » Accounts Payable
Comparable Companies
XPAR:ALCLS XPAR:NANO XPAR:IVA XPAR:GNFT XPAR:OSE XPAR:ALSEN XPAR:DBV XPAR:TNG XPAR:MAAT XPAR:ADOC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IPHA:USA 0EVI:UK IPH:France IDDA:Germany IDDA:Germany IDD:Germany
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.